학술논문
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
Document Type
Article
Author
Ruperto, Nicolino; Brunner, Hermine I; Synoverska, Olga; Ting, Tracy V; Mendoza, Carlos Abud; Spindler, Alberto; Vyzhga, Yulia; Marzan, Katherine; Grebenkina, Lyudmila; Tirosh, Irit; Imundo, Lisa; Jerath, Rita; Kingsbury, Daniel J; Sozeri, Betul; Vora, Sheetal S; Prahalad, Sampath; Zholobova, Elena; Butbul Aviel, Yonatan; Chasnyk, Vyacheslav; Lerman, Melissa; Nanda, Kabita; Schmeling, Heinrike; Tory, Heather; Uziel, Yosef; Viola, Diego O; Posner, Holly B; Kanik, Keith S; Wouters, Ann; Chang, Cheng; Zhang, Richard; Lazariciu, Irina; Hsu, Ming-Ann; Suehiro, Ricardo M; Martini, Alberto; Lovell, Daniel J; Cuttica, R; Akikusa, J; Chaitow, J; Wouters, C; Oliveira, S; Neiva, CLS; Santiago, M; Silva, CA; Terreri, MT; Magalhaes, C; De Souza, V; Bandeira, M; Chédeville, G; Houghton, K; Vazquez-Del Mercado, M; Rizo Rodriguez, J; Kobusinska, K; Alexeeva, E; Calvo Penades, I; Boteanu, AL; Kasapcopur, O; Poyrazoglu, MH; Erguven, M; Ozen, S; Al-Abadi, E; Bohnsack, J; Carrasco, R; Dare, J; Gottlieb, B; Wahezi, D; Jung, L; Klein-Gitelman, M; Zhang, Y; Wagner-Weiner, L; Tarvin, S; Vehe, RK; Chiraseveenuprapund, P; Rivas-Chacon, R; De La Pena, W; Sagcal-Gironella, ACP; Weiss, JE
Source
The Lancet; November-December 2021, Vol. 398 Issue: 10315 p1984-1996, 13p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic arthritis (JIA).